EMD Chemicals Expands Multi-Analyte Portfolio Via Collaboration With MitoSciences

EMD Chemicals Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, a leading supplier of assays, reagents, and chemicals for the life science and drug discovery market, announced today a research and commercial collaboration with MitoSciences Inc., a leading developer of antibodies and immunoassays for measuring mitochondrial and metabolic function, whose products are used by basic researchers, drug developers and clinicians.

The new collaboration allows for co-development of high-quality multiplex immunoassay products for the WideScreenTM BeadPlexTM assay platform for the detection and profiling of mitochondrial toxicity and activity. This enables EMD Chemicals to expand its already extensive offering in the multiplex biomarker, drug discovery and drug development markets. Under the terms of the agreement, MitoSciences has granted EMD Chemicals exclusive rights to a large new offering of currently unlicensed monoclonal antibodies for monitoring mitochondrial toxicity and bioactivity. MitoSciences will work exclusively with EMD Chemicals to validate the new WideScreen assays for use in drug screening applications.